I2O Pharma specializes in developing oral versions of injectable drugs, using technology licensed from the Hebrew University of Jerusalem. The company is now planning human trials. I2O Pharma is supported byAurum Ventures MKI. The company is inactive and the updating process will be stopped since 11/2018.